On April 13, the Food and Drug Administration of the Ministry of Health and Welfare of the Republic of China (TFDA) issued a drug recall announcement regarding “Kinzaten Ophthalmic Solution 0.25mg/ml ‘Kingdom’” manufactured by Kingdom Pharmaceutical Co., Ltd. The manufacturer reported that during ongoing stability testing of the specified batches, the preservative Propyl Paraben was found to be lower than the originally approved specification, prompting a voluntary recall following safety and quality evaluation.

Basic Information of the Recalled Drug

  • Drug / Product Name: Kinzaten Ophthalmic Solution 0.25mg/ml (“Kingdom” - Ketotifen).
  • Indications: Temporary prevention of ocular itching due to allergic conjunctivitis.
  • Active Ingredient: Ketotifen Fumarate.
  • License Number: MOHW Drug Manufacturing No. 057143.
  • Batch Numbers: TC015, TM004, TP007, TR011, TR013, UA011, UB002, and UG007.
  • License Holder: Kingdom Pharmaceutical Co., Ltd.
  • Product Reference Image:

Kinzaten Ophthalmic Solution 0.25mg/ml (“Kingdom” - Ketotifen)

Drug Recall Details

  • Recall Classification: Class 2[i].
  • Recall Document Number: FDA Drug Division Doc No. 1070011968.
  • Issue Date: April 13, 2018.
  • Release Date: April 26, 2018.
  • Reason for Recall: Voluntary report by the manufacturer indicating that ongoing stability testing at 6, 9, and 12 months showed that the preservative Propyl Paraben was lower than the originally approved specification.

Further Reading

  1. Introduction and Management of the MOHW TFDA Drug Recall Grading System
✦ Independent Journalism · Reader Support ✦

Support Independent Perspectives & In-Depth Insights

Every thoughtful analysis and candid critique comes from our dedication to truth and quality. We choose not to follow sensational algorithms or clickbait headlines.

Sustaining independent research requires reader support. Make a one-time or monthly contribution, securely processed by Google.

Payments secured by Google · Manage or cancel anytime in your Google Account